Clinical Guideline for Treatment of Symptomatic Thoracic Spinal Stenosis


Thoracic spinal stenosis is a relatively common disorder causing paraplegia in the population of China. Until nowadays, the clinical management of thoracic spinal stenosis is still demanding and challenging with lots of questions remaining to be answered. A clinical guideline for the treatment of symptomatic thoracic spinal stenosis has been created by reaching the consensus of Chinese specialists using the best available evidence as a tool to aid practitioners involved with the care of this disease. In this guideline, many fundamental questions about thoracic spinal stenosis which were controversial have been explained clearly, including the definition of thoracic spinal stenosis, the standard procedure for diagnosing symptomatic thoracic spinal stenosis, indications for surgery, and so on. According to the consensus on the definition of thoracic spinal stenosis, the soft herniation of thoracic discs has been excluded from the pathological factors causing thoracic spinal stenosis. The procedure for diagnosing thoracic spinal stenosis has been quite mature, while the principles for selecting operative procedures remain to be improved. This guideline will be updated on a timely schedule and adhering to its recommendations should not be mandatory because it does not have the force of law.

This clinical guideline for symptomatic thoracic spinal stenosis has been developed by ninety‐seven spinal surgery specialists from mainland China and is for spinal surgeons to consult with the aim of standardizing their diagnostic and therapeutic procedures and improving the clinical outcomes of patients with symptomatic thoracic spinal stenosis. A project team from Peking University Third Hospital was responsible for the drafting this guideline, this team being financially supported by a grant from the Science and Technology Commission of Beijing. This guideline will be updated in future to incorporate progress in fundamental research and clinical practices. Because this guideline does not have the force of law, adhering to its recommendations is not mandatory. Should litigation occur, this guideline cannot be used as a legal justification of treatment choices.

Journal of Orthopedic Oncology offers information in all aspects of primary, malignant tumors. Osteosarcoma, Ewing's sarcoma, chondrosarcoma, chordoma, and soft tissue sarcomas etc., it also deals with diagnostic methods, therapeutic approaches, clinical, laboratory research and reconstructive techniques.

The Journal includes a wide range of fields in its discipline to create a platform for the authors to make their contribution towards the journal and the editorial office promises a peer review process for the submitted manuscripts for the quality of publishing.

The Journal uses Editorial Tracking System for quality in review process. Editorial Manager is an online manuscript submission, review and tracking systems. Review processing is performed by the editorial board members of Orthopedics & Oncology or outside experts; at least two independent reviewer’s approval followed by editor approval is required for acceptance of any citable manuscript. Authors may submit manuscripts and track their progress through the system.

The Journal Considers Research article, Review articles, editorial, letter, case reports, short communications, original articles from leading scientists and scholars around the world in all areas of related to Malignantosteoid, Multilobular tumour of bone, Chondrosarcoma, Chordoma, Osteosarcoma, Ewing's sarcomaetc., which come under the scope of the journal.

You may submit your manuscript as an e-mail attachment to the Editorial Office at,

Best Regards,


Editorial Team

Journal of Orthopedic Oncology

WhatsApp: +44-1470-490003